| abstract |
A pharmaceutical composition comprising an isolated antibody comprising a heavy chain variable domain sequence comprising SEQ ID NO: 3 and a light chain variable domain sequence comprising SEQ ID NO: 4, and wherein said antibody is specifically binds to human IL-17 receptor A, for use in a method of treating psoriasis in an adult or juvenile psoriasis patient, wherein the method comprises administering to said patient the pharmaceutical product in a single or divided dose of approximately 70 to about 300 mg of antibody per dose administered at time "0" (first administration), one week after time "0", and then given every two weeks after week one administration. |